Track the spend, not just the headline. In its annual report for fiscal 2022, filed February 22, 2023, Eli Lilly reported research and development expense of about $7.19 billion, compared with roughly $7.03 billion in 2021 and about $6.09 billion in 2020. The trajectory is the point: this is a research budget rising steadily, year over year.
For a company of Lilly’s scale, R&D is the forward-looking line on the income statement — it is what the current business spends to create the next one. A climb from roughly $6.1 billion to $7.2 billion in two years reflects a deliberate decision to push hard on the pipeline rather than harvest existing products.
The fundamentals-first read is to weigh that spend against what it is meant to produce. R&D this large only pays off if the candidates it funds reach the market — and the timeline between dollars spent and products approved runs years. The 10-K records the investment; it does not, and cannot, record the return.
Read forward from early 2023, the open question is conversion efficiency: how much approved-product value Lilly ultimately gets per research dollar at this elevated spend. As of this filing, the ledger shows a company investing aggressively in its own future — the verdict on that investment is still ahead of the document.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.